BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf whole-cell cancer immunotherapies, with lead candidate Bria-IMT in pivotal Phase 3 for metastatic breast cancer and a Bria-OTS+ platform extending into prostate, lung, melanoma, and ovarian cancers.
- Company typePublic
- Founded2014
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BriaCell Therapeutics does
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology biotechnology company developing targeted whole-cell cancer immunotherapies. The company's lead asset, Bria-IMT, is an off-the-shelf cell-based immunotherapy with FDA Fast Track designation currently in pivotal Phase 3 evaluation (the Bria-ABC study) for metastatic breast cancer, particularly in patients who have failed antibody-drug conjugate (ADC), checkpoint inhibitor (CPI), and CDK4/6 inhibitor therapies and those with CNS metastases. The second-generation Bria-OTS+ platform is engineered to express 15 unique HLA types across four independent cell lines, enabling personalized off-the-shelf immunotherapy matched to greater than 99% of patients via a simple saliva test.
The pipeline built on the Bria-OTS+ platform includes Bria-BRES+ (Phase 1/2a breast cancer, FDA-cleared), Bria-PROS+ (Phase 1/2a prostate cancer, NCI-funded), Bria-MEL+ (preclinical melanoma), Bria-LUNG+ (lung cancer, trials planned 2027), and Bria-OVA+ (ovarian). Phase 2 results demonstrated 16.6 months median overall survival in heavily pre-treated metastatic breast cancer patients with up to 2-fold improvement versus literature comparators and a 71% intracranial objective response rate in CNS metastases.
BriaCell has no commercialized products and is pre-revenue. The company funds operations through repeated public equity offerings (over $85 million raised across 2024-2026), a $2 million NCI SBIR grant, and a $4 million strategic investment from Prevail Partners. Go-to-market is conducted via enterprise field sales targeting major cancer centers, with 79 clinical trial sites across 23 US states. Distribution is through FDA-regulated clinical supply chains. BriaCell is publicly traded on Nasdaq (BCTX) and TSX (BCT), with corporate offices in Philadelphia, PA and West Vancouver, BC, and a majority-owned subsidiary (BriaPro Therapeutics Corp., ~78% owned) focused on additional cancer immunotherapy programs including Soluble CD80.
BriaCell Therapeutics firmographics
Firmographics- Name
- BriaCell Therapeutics
- Legal name
- BriaCell Therapeutics Corp.
- Website
- https://briacell.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BriaCell Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf whole-cell cancer immunotherapies, with lead candidate Bria-IMT in pivotal Phase 3 for metastatic breast cancer and a Bria-OTS+ platform extending into prostate, lung, melanoma, and ovarian cancers.
- Ownership category
- akta.pro rank
BriaCell Therapeutics industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)
- akta.pro secondary industries
- Breast Oncology (HLAKAFAJ), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where BriaCell Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BriaCell Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development: Pre-revenue clinical-stage biotechnology company developing novel immunotherapies for cancer treatment. No commercialized products yet. Revenue will be generated through drug sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
BriaCell Therapeutics product offering
Product offeringCore offering
BriaCell Therapeutics is a clinical-stage immuno-oncology biotechnology company developing targeted cell-based immunotherapies for cancer treatment. The company's lead candidate, Bria-IMT, is an off-the-shelf whole-cell immunotherapy in pivotal Phase 3 development for metastatic breast cancer with FDA Fast Track designation. The Bria-OTS+ next-generation platform uses HLA-matching technology to deliver personalized off-the-shelf immunotherapies across multiple cancer types including breast, prostate, lung, melanoma, and ovarian cancers.
Product overview
BriaCell Therapeutics is a clinical-stage immuno-oncology company developing a portfolio of targeted cellular immunotherapies for cancer treatment. The company's lead product is Bria-IMT™, an off-the-shelf cell-based immunotherapy with FDA Fast Track designation in pivotal Phase 3 development for metastatic breast cancer. The Bria-OTS+™ platform serves as the next-generation foundation, enabling personalized off-the-shelf treatments through HLA matching across multiple cancer types including breast (Bria-BRES+™), prostate (Bria-PROS+™), lung (Bria-LUNG+™), melanoma (Bria-MEL+™), and ovarian (Bria-OVA+™) cancers. The company also maintains BriaDx™ as a companion diagnostic for patient selection. BriaCell operates with corporate offices in Philadelphia, PA and West Vancouver, BC, and is listed on Nasdaq (BCTX) and Toronto Stock Exchange (BCT).
Differentiator
Problem solved
Functional benefit
Brands
- Bria-IMT: Lead candidate - patented, off-the-shelf, cell-based, targeted immunotherapy for metastatic breast cancer with FDA Fast Track designation
- Bria-OTS
- Bria-OTS+
- Bria-MEL+
- Bria-LUNG+
- Bria-PROS+
- Bria-BRES+
- Bria-OVA+
- BriaVax
- BriaDx
Products and services
- Bria-IMT Patented, off-the-shelf, cell-based targeted immunotherapy that activates the patient's immune system to specifically kill cancer cells. FDA Fast Track designated lead candidate in pivotal Phase 3 study for metastatic breast cancer, with demonstrated activity in CPI and ADC resistant patients and patients with CNS metastases.
- Bria-OTS+/Bria-OTS+ Next-generation personalized off-the-shelf cell-based immunotherapy platform engineered to express multiple immune-activating cytokines and co-stimulatory molecules. Designed to express 15 unique HLA types in 4 independent cell lines to provide matched treatment to greater than 99% of patients through a simple saliva test.
- Bria-PROS+ Next-generation personalized off-the-shelf immunotherapy candidate for prostate cancer. Activates adaptive and innate immunity including T-cells, dendritic cells, and natural killer cells.
- Bria-BRES+ Next-generation personalized off-the-shelf immunotherapy candidate for breast cancer within the Bria-OTS+ platform with enhanced immune engagement features. FDA cleared for Phase 1/2a clinical study.
- Bria-LUNG+
Quantifiable outcome
- Median overall survival of 16.6 months in heavily pre-treated metastatic breast cancer patients (Phase 2 final results)
- +6 more outcomes
Companies that use BriaCell Therapeutics
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles2 records
BriaCell Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BriaCell Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered strategic, minor and core.
- UneedlestrategicNetherlands-based microneedle drug-delivery company. Memorandum of Understanding to support commercial readiness of BriaCell's Bria-IMT using Uneedle's proprietary intradermal microneedle technology. Technology currently being used in Phase 3 study for faster, more convenient administration.
- Receptor.AIminorCollaboration uses Receptor.AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro subsidiary.
- Memorial Sloan Kettering Cancer Center's Therapeutics AcceleratorstrategicCollaboration to support development of Bria-OTS+ platform including Phase 1 clinical trial for breast cancer. Partnership leverages MSK's clinical and manufacturing expertise to accelerate immunotherapy development.
- MSK Accelerator 2025strategicBriaCell selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer. Provides manufacturing, IND, and clinical protocol support.
- Prevail InfoWorks, LLCcorePrevail InfoWorks acts as Contract Research Organization providing clinical services and real-time data analytics to support BriaCell's pivotal study in advanced metastatic breast cancer.
- Terasaki Foundation LaboratoryminorResearch agreement with Terasaki Foundation Laboratory for scientific collaboration.
- ThinkEquitycoreThinkEquity serves as sole placement agent for multiple public offerings including the $8.5 million (September 2024), $5.0 million (May 2024), $13.8 million (April 2025), $15 million (July 2025), $30 million (January 2026), and $4.7 million (June 2026) offerings.
- BeiGenestrategicClinical supply agreement for Bria-OTS study evaluating Bria-OTS in combination with anti-PD-1 antibody tislelizumab in advanced cancers.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
BriaCell Therapeutics competitors and assessment
Company assessmentDirect peers
- Adaptimmune Therapeutics: Cell therapy biotech developing SPEAR T-cell receptor therapies for solid tumors including synovial sarcoma. Comparable as a clinical-stage cell therapy company targeting solid tumor indications with similar late-stage clinical and regulatory pathway.
- Iovance Biotherapeutics: Clinical-stage cell therapy biotech with FDA-approved tumor-infiltrating lymphocyte (lifileucel) therapy for solid tumors. Directly comparable as a clinical-stage cell-based immunotherapy company pursuing regulatory approval in oncology with similar manufacturing complexity and pre-commercial profile.
- Gritstone bio: Clinical-stage biotech developing personalized neoantigen cancer vaccines (GRANITE platform) for solid tumors. Directly comparable as a personalized cancer immunotherapy developer with similar HLA/neoantigen matching approach and clinical-stage profile in oncology.
- Allogene Therapeutics: Allogeneic CAR-T cell therapy developer with multiple clinical programs in hematologic and solid tumors. Directly comparable as an off-the-shelf cell therapy platform targeting cancer, with similar allogeneic manufacturing and HLA-related considerations.
Emerging players
- MacroGenics: Clinical-stage oncology biotech developing antibody-based therapeutics including ADCs and bispecifics. Comparable as a clinical-stage oncology company developing novel biologics for metastatic breast cancer and other solid tumors with similar late-stage development profile.
- Genexine: Clinical-stage Korean biotech developing immuno-oncology and cell therapy products including GX-188E therapeutic HPV vaccine. Comparable as a clinical-stage immuno-oncology company with cell therapy and vaccine programs targeting cancer, with similar pipeline breadth and stage of development.
- Innate Pharma: Clinical-stage immuno-oncology company developing antibody-based therapeutics engaging innate immune cells. Comparable as a clinical-stage oncology immunotherapy company with similar development stage, partnership-driven model (including with AstraZeneca and Sanofi), and small-mid cap profile.
- Compugen: Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting novel immune checkpoints. Comparable as a clinical-stage oncology biotech pursuing novel immunotherapy approaches with similar small-cap profile and partnership-heavy business model.
Broad incumbents
- BioNTech: Large oncology immunotherapy company with individualized neoantigen cancer vaccine programs (BNT122/iNeST) and a broad mRNA-based oncology pipeline. Comparable in pursuing personalized cancer immunotherapy approaches with HLA/neoantigen targeting, though with much larger scale and COVID-vaccine cash flows.
- Moderna: Large biotech with extensive oncology mRNA vaccine pipeline including personalized neoantigen programs (mRNA-4157/V940 with Merck). Comparable in pursuing personalized cancer vaccine approaches but operating at much greater scale with COVID vaccine cash flows.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
BriaCell Therapeutics social profiles
Digital presenceBriaCell Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BriaCell Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
BriaCell Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
BriaCell Therapeutics funding detail
Funding detailFunding overview
Funding rounds12 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BriaCell Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BriaCell Therapeutics
What does BriaCell Therapeutics do?
BriaCell Therapeutics is a clinical-stage immuno-oncology biotechnology company developing targeted cell-based immunotherapies for cancer treatment. The company's lead candidate, Bria-IMT, is an off-the-shelf whole-cell immunotherapy in pivotal Phase 3 development for metastatic breast cancer with FDA Fast Track designation. The Bria-OTS+ next-generation platform uses HLA-matching technology to deliver personalized off-the-shelf immunotherapies across multiple cancer types including breast, prostate, lung, melanoma, and ovarian cancers.
Is BriaCell Therapeutics a public or private company?
BriaCell Therapeutics is a public company. It is classified as public and is currently operating.
When was BriaCell Therapeutics founded?
BriaCell Therapeutics was founded in 2014. It employs 11 to 50 people.
Where is BriaCell Therapeutics based?
BriaCell Therapeutics is headquartered in New York, United States, in the North America region.
How does BriaCell Therapeutics make money?
One revenue line is on record: pharmaceutical Development.
Who are BriaCell Therapeutics's main competitors?
Direct peers on record are Adaptimmune Therapeutics, Iovance Biotherapeutics, Gritstone bio and Allogene Therapeutics. Emerging players are MacroGenics, Genexine, Innate Pharma and Compugen. Broad incumbents are BioNTech and Moderna.
Does BriaCell Therapeutics have an API?
No public API is recorded for BriaCell Therapeutics.
What industry is BriaCell Therapeutics in?
BriaCell Therapeutics's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAKAFAJ, Breast Oncology. Its NAICS code is 325414 and its SIC code is 2836.